It was shown that in PD patients treated with STN-DBS, neuropeptide Y levels increase despite high leptin levels and it was argued that DBS interferes with the inhibitory action of leptin in the hypothalamus (19, 25). The gene discussed is LEP; the disease is Parkinson disease.